MiNK Therapeutics (NASDAQ:INKT) Given New $35.00 Price Target at HC Wainwright

MiNK Therapeutics (NASDAQ:INKT) had its price target hoisted by HC Wainwright from $9.00 to $35.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price suggests a potential upside of 273.53% from the stock’s current price. HC Wainwright also issued estimates for MiNK Therapeutics’ FY2029 earnings at ($0.02) EPS.

Separately, Robert W. Baird decreased their target price on shares of MiNK Therapeutics from $80.00 to $40.00 and set an “outperform” rating for the company in a report on Friday, November 15th.

MiNK Therapeutics Price Performance

Shares of INKT opened at $9.37 on Tuesday. MiNK Therapeutics has a one year low of $4.56 and a one year high of $19.00. The company has a 50-day moving average of $8.37 and a two-hundred day moving average of $7.73. The stock has a market cap of $37.13 million, a price-to-earnings ratio of -2.40 and a beta of 0.17.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.